Category: Uncategorized

I am a passionate health, beauty, and lifestyle writer based in the south of the UK. Balancing my love for writing with raising my two children, I hopefully bring a relatable, insightful perspective to my articles.
  • ADHD Medication Shortages in the UK: What Is Causing Them, Who Is Most Affected, and What Patients Can Actually Do

    ADHD Medication Shortages in the UK: What Is Causing Them, Who Is Most Affected, and What Patients Can Actually Do

    If you or someone you care for takes methylphenidate or lisdexamfetamine for ADHD, there is a reasonable chance you have already run into a wall at the pharmacy. A prescription in hand, a pharmacist apologising, and the instruction to try elsewhere. For some people this has been a recurring experience since 2023. The ADHD medication shortage UK 2026 is not a brief supply blip, it reflects a structural problem that regulators, manufacturers, and the NHS have struggled to resolve.

    Pharmacist reviewing a prescription during the ADHD medication shortage UK 2026
    Photo by cottonbro studio on Pexels

    I want to be honest about what we do and do not know here, because there is a lot of speculation circulating online. What is clear is that the shortage is real, measurable, and damaging. What is less clear is exactly when it will be fully resolved. This article covers the documented causes, who is being hit hardest, and what options exist for people caught in the gap right now.

    Why the ADHD medication shortage is happening

    There are several overlapping reasons, and none of them alone fully explains the scale of the problem.

    First, demand has risen sharply. As covered in the surge in adult ADHD diagnoses across Britain, the number of people being assessed and diagnosed has grown considerably over the past four years. More diagnoses mean more prescriptions, and manufacturing capacity did not scale alongside that growth.

    Second, methylphenidate and lisdexamfetamine are controlled drugs under the Misuse of Drugs Regulations 2001. This means their production is subject to quotas set at both national and international level. The International Narcotics Control Board sets global manufacturing limits for controlled substances, and increasing production legally takes time. The MHRA and the Department of Health and Social Care have been engaging with manufacturers to raise those limits, but the process is slow.

    Third, there are supply chain vulnerabilities specific to pharmaceutical manufacturing. The active pharmaceutical ingredients for many stimulant medications are produced by a small number of facilities globally. Disruptions at any of those sites, whether through regulatory inspections, raw material shortages, or production issues, create ripple effects across entire markets. The UK is not uniquely exposed here, but it is not insulated either. The MHRA’s medicine supply notifications page has tracked multiple alerts across different formulations since 2023.

    Fourth, the shortage feeds on itself. When one formulation or brand becomes unavailable, patients and pharmacies seek alternatives. That increased demand for the alternative then creates a secondary shortage. By mid-2025 this was visible across multiple methylphenidate brands simultaneously.

    Which medications and formulations are most affected

    The picture shifts week to week, which is part of what makes this so difficult to navigate. Broadly speaking, modified-release methylphenidate formulations have been the most consistently affected. Brands including Concerta XL, Equasym XL, and Medikinet XL have all experienced periods of limited availability. Immediate-release methylphenidate tablets have generally been more available, though not always in the specific dose required.

    Lisdexamfetamine (Vyvanse, and the generic lisdexamfetamine dimesylate that became available from 2024) has also been affected, though the pattern has been somewhat different, more localised to certain regions and wholesalers rather than a blanket national scarcity.

    Atomoxetine (Strattera and generics), which is a non-stimulant ADHD medication, has generally remained more available. This matters for patients and prescribers considering alternatives, though atomoxetine does not suit everyone and takes several weeks to reach therapeutic effect.

    Who is most affected and why

    Adults newly diagnosed with ADHD are often in the most precarious position. Shared care agreements, where a GP takes over prescribing from a specialist, are not always in place or functioning smoothly. When a shortage strikes and a patient needs a switch in formulation or brand, they may find their GP unwilling to adjust the prescription without specialist input, and their specialist clinic has a waiting list for follow-up appointments stretching months.

    Children on stable regimens are also seriously affected. Missing doses is not trivial. For many children, consistent medication is directly tied to their ability to function at school, manage emotional regulation, and sleep properly. Parents have reported significant distress trying to source medication across multiple pharmacies, sometimes travelling considerable distances.

    People in rural areas, those without easy transport, and those without the time or confidence to advocate for themselves are disproportionately affected. Navigating a shortage requires persistence, flexibility, and often the ability to contact multiple services, none of which should be prerequisites for accessing a prescribed medicine.

    The NHS waiting list problem also intersects here painfully. As I have written about before, the pressures on NHS waiting lists are already pushing patients towards DIY solutions, and ADHD medication shortages accelerate that pressure in a particularly risky direction. Some people have reported sourcing medication from private online pharmacies of questionable legitimacy. That route carries real risks, including receiving counterfeit or incorrectly dosed medication.

    What patients can actually do right now

    This is where I want to be genuinely useful rather than just explain the problem.

    Contact multiple pharmacies before assuming the medication is unavailable everywhere. Stock levels vary significantly between pharmacies even within the same town. Independent pharmacies sometimes have access to different wholesalers than large chains. Ring around. It is tedious, but it works more often than people expect.

    Ask your pharmacist to check the specific manufacturer, not just the drug name. If Concerta XL is unavailable, a generic methylphenidate modified-release from a different manufacturer may be in stock. Your prescriber may need to adjust the prescription, but pharmacists can often advise on what equivalents are available and contact your GP directly if you give consent.

    Talk to your prescriber about a contingency plan before you run out. If you have a week’s supply remaining, that is the time to contact your GP or specialist, not when you are on your last tablet. Ask specifically whether a different formulation or brand could be prescribed temporarily, and whether immediate-release tablets could bridge a gap.

    Check the MHRA supply notifications and the ADHD UK charity’s resources. ADHD UK has published practical, up-to-date guidance on navigating the shortage, and their information is more current than most NHS pages on the subject.

    If you are self-funding privately, ask your prescribing clinician about licensed alternatives. Guanfacine extended-release (Intuniv) is licensed for ADHD in children and adolescents, and some adults are prescribed it off-label. It is not a stimulant and does not suit everyone, but for some patients it provides a workable bridge.

    Document everything. Keep records of which pharmacies you contacted, what you were told, and when. If you are missing doses due to supply failures and this is affecting your health or your child’s education, that record may be relevant if you need to escalate a complaint or access emergency provision.

    What regulators and the NHS are doing

    The MHRA has issued several guidance documents and supply notifications since 2023, and the Department of Health and Social Care has been in ongoing discussions with manufacturers. NHS England has also updated guidance for prescribers around switching formulations during shortage periods.

    Progress is real, but uneven. Some formulations have returned to more stable supply while others remain constrained. The honest answer is that full resolution is not imminent. The structural factors, controlled drug quotas, manufacturing concentration, and rising demand, will take time to fully address.

    If you are managing ADHD in 2026 and feeling let down by the system, that frustration is legitimate. The shortage is not a personal failing, a pharmacy problem you can easily solve, or something that should require you to spend hours on the phone every month. It is a systemic issue, and the people bearing the cost of it are patients who had no say in creating it.

  • NHS Mental Health Waiting Times: What the Statistics Actually Hide

    NHS Mental Health Waiting Times: What the Statistics Actually Hide

    NHS mental health waiting times are published regularly, reported in Parliament, and cited in policy documents as evidence that the system is, or is not, performing. The numbers look precise. They are not. Behind the headline figures lies a methodological tangle that obscures how long people genuinely wait, how many give up before being seen, and whether those who do reach treatment receive something that actually helps.

    I’ve spent time reading through NHS England’s own data releases alongside independent analysis from the Kings Fund and the Mental Health Foundation, and what becomes clear is that the official statistics, while not fabricated, are structured in a way that consistently flatters the picture. That matters enormously when mental health provision is already under pressure and when the people most affected rarely have the energy to interrogate the numbers on their behalf.

    Person sitting alone in a hospital corridor, reflecting the reality behind NHS mental health waiting times
    Photo by Yiğit KARAALİOĞLU on Pexels

    How NHS Talking Therapies waiting times are measured

    NHS Talking Therapies, formerly known as IAPT (Improving Access to Psychological Therapies), is the largest talking therapy service in the world by volume. The government’s stated standard is that 75% of people should begin treatment within six weeks of referral. The NHS publishes monthly data showing compliance with this target, and in most recent reporting periods that target appears to be met or closely approached nationally.

    The problem is what “referral” and “treatment” mean in this context. The waiting time clock starts when a referral is received by the service, but it only starts ticking towards the headline figure once the referral has been accepted. Referrals that are rejected or redirected, often because the person’s needs are assessed as too complex for IAPT-level support, disappear from the waiting time data entirely. People who self-refer and then wait weeks for even an initial triage call are frequently not counted in the headline metric either, depending on how local trusts log that first contact.

    NHS England’s own technical guidance acknowledges these definitional issues. What it does not do is prominently flag them in the summary statistics that end up in ministerial statements and press releases.

    CAMHS waiting times and the missing data problem

    Child and Adolescent Mental Health Services present an even murkier statistical picture. Unlike NHS Talking Therapies, CAMHS does not operate under a single nationally mandated waiting time standard. The NHS Long Term Plan set ambitions rather than enforceable targets, which means reporting is inconsistent across integrated care systems. Some trusts measure from GP referral; others from the point of specialist triage. Some include community eating disorder services; others do not.

    The result, as the Centre for Mental Health has consistently noted, is that a child waiting 22 weeks in one part of England might be recorded differently from a child with an identical wait in another. Comparing CAMHS waiting time data across regions is therefore largely meaningless without drilling into the methodology of each reporting trust, something no anxious parent with a struggling teenager has the time or technical knowledge to do.

    What CAMHS data also tends to obscure is the number of children and young people who are referred and then assessed as not meeting the threshold for service. This is not a small group. Referral rejection rates vary but can be substantial. Those young people do not vanish, they wait again, often returning to their GP and cycling through the system multiple times before reaching support. That cycle is invisible in the headline figures.

    NHS mental health waiting times data on a clipboard showing statistics and figures
    Photo by RDNE Stock project on Pexels

    Dropout rates: the statistic that rarely makes the headlines

    Even when people do enter treatment, a significant proportion leave before completing their course. NHS Talking Therapies data includes a “completed treatment” category, but the gap between people who start treatment and those who are eventually coded as completing it tells its own story. Roughly a quarter of people who begin a course of therapy do not finish it, according to figures from NHS England’s published datasets.

    Dropout is not a neutral event. It can represent recovery, certainly. But it can also represent someone who found the waiting so demoralising that motivation collapsed, someone who was offered a form of therapy that did not suit their presentation, or someone whose life circumstances, childcare, work, transport, made attending sessions impossible. The data does not distinguish between these. A person coded as “dropped out” is simply removed from the recovery rate calculation, which means the headline recovery statistics are drawn from the subset of people who both completed treatment and were assessed at the end. That is not a representative sample.

    This connects to a broader issue with how NHS mental health waiting times interact with the growing tendency for people to pursue DIY health solutions while waiting. When the system feels opaque and inaccessible, people turn elsewhere, sometimes helpfully, sometimes not.

    What the figures conceal about severity and need

    NHS Talking Therapies is designed for mild-to-moderate conditions: anxiety, depression, phobias, mild OCD. It is not designed for psychosis, personality disorders, complex trauma, or severe and enduring mental illness. Yet because IAPT is the most visible and most numerically reported part of the mental health system, its statistics dominate public perception of how the NHS is performing on mental health.

    People with more serious needs are largely invisible in published waiting time data. Secondary care psychiatric services, community mental health teams, inpatient provision, these operate under different reporting frameworks, with far less transparency. The NHS dashboard that looks relatively orderly at the IAPT level tells you almost nothing about what happens to someone who presents to their GP with symptoms that are beyond mild-to-moderate. That person may wait considerably longer, with less visibility and less accountability built into the process.

    I’d argue this is the most significant gap in the public picture. The presentable statistics we are shown mostly describe the part of the system that performs best. The parts that struggle most are also the parts measured least.

    Why the data is built this way

    It would be too simple to say this is deliberate obfuscation. The architecture of NHS mental health waiting time data reflects how the system developed: IAPT was built with reporting infrastructure from the start, precisely because it was a new national programme that needed to demonstrate value. Older services were not built that way and retrofitting consistent national data collection onto a fragmented set of legacy services is genuinely hard.

    That said, the effect of this patchwork is that ministers, commissioners, and the public receive a partial and systematically optimistic view of performance. The parallel boom in mental health apps and digital tools has partly grown in the space this leaves, people who cannot access or do not trust NHS provision looking for alternatives, many of which carry their own evidence problems.

    Reading the numbers more honestly

    If you want a more honest picture of NHS mental health waiting times, the place to start is not the dashboard headline. Look at the number of people referred but not treated, not just those waiting for treatment. Look at the proportion of completed treatment courses versus starts. Look at how your local integrated care system reports CAMHS data and what definition of “waiting time” it uses.

    For researchers and journalists, NHS England’s Mental Health Services Dataset (MHSDS) contains more granular information than the headline publications, though navigating it requires some technical patience. The Health Foundation and the Kings Fund publish accessible analyses that do much of the interpretive work.

    Data integrity in health systems matters beyond mental health, of course. Questions about how clinical information is stored, processed, and accessed are becoming increasingly pressing as more services move to cloud and AI-assisted tools, and providers like dijitul.ai are part of a growing conversation about where patient-sensitive data actually lives and who can reach it.

    The point, on NHS mental health waiting times, is not that the numbers are lies. It is that they are carefully scoped truths, and the scope excludes a lot. Until the measurement framework is reformed to include rejected referrals, dropout context, and consistent CAMHS reporting, the statistics will keep telling a story that is tidier than the reality experienced by the people waiting.

    Frequently Asked Questions

    What is the official NHS waiting time target for mental health treatment?

    For NHS Talking Therapies (formerly IAPT), the target is that 75% of patients should begin treatment within six weeks of referral, with 95% seen within 18 weeks. No equivalent enforceable national target exists for CAMHS, which is one reason CAMHS waiting time data is so inconsistent across England.

    Why do NHS mental health waiting time statistics look better than patient experience suggests?

    The main reason is how the clock is measured. Waiting times are typically counted from when a referral is accepted, not when it is received, and rejected or redirected referrals drop out of the data entirely. This means people who are turned away from services, sometimes repeatedly, are not reflected in the headline figures.

    How long are children typically waiting for CAMHS in England?

    Published CAMHS waiting times vary substantially by region and by how individual trusts define the start of the wait. NHS England’s Mental Health Services Dataset shows some children waiting over a year in certain areas. Because reporting definitions differ between trusts, direct comparisons are unreliable without examining local methodology.

    What happens to people who drop out of NHS Talking Therapies before completing treatment?

    People who do not complete their therapy course are typically excluded from the recovery rate calculations published by NHS England, meaning the headline recovery statistics only describe those who completed treatment and were assessed at the end. Dropout rates of around 25% are not uncommon nationally, but the reasons behind them are rarely broken down in published data.

  • Why the UK’s Rollout of Genomic Medicine Is Moving Slower Than the Headlines Suggest

    Why the UK’s Rollout of Genomic Medicine Is Moving Slower Than the Headlines Suggest

    The government’s pitch for genomic medicine is genuinely compelling. Sequence your DNA, understand your disease risk, target your cancer treatment precisely, and spare you years of misdiagnosis. The NHS Genomic Medicine Service (GMS), launched in 2018 and formally expanded through the 2020s, is supposed to be the engine that delivers that future to every patient in England. On paper, the UK leads the world. In practice, the picture is considerably messier, and I think most patients would be surprised by how far day-to-day clinical reality lags behind the announcements.

    Scientist examining NHS genomic medicine UK sequencing data on a laboratory screen
    Photo by Tima Miroshnichenko on Pexels

    This is not a story about failure. The science is real, the ambition is right, and there are places where genomic medicine is genuinely changing lives today. But the gap between government rhetoric and what most patients actually encounter is wide enough to deserve honest examination, and that gap has consequences.

    What the NHS Genomic Medicine Service actually is

    The GMS operates through seven Genomic Laboratory Hubs across England, each covering a large geographic region. These hubs process genetic tests ordered by clinicians, link into a shared NHS Genomic Medicine Service dataset, and are meant to be the infrastructure through which whole genome sequencing eventually becomes routine. Genomics England, a company owned by the Department of Health, runs the 100,000 Genomes Project data and feeds into this infrastructure. Together, these bodies represent a genuinely significant investment: the government has committed hundreds of millions of pounds to the programme since its inception.

    The GMS focuses primarily on rare diseases and cancer genomics. For a child with an undiagnosed rare condition, a whole genome sequence can end a diagnostic odyssey that might otherwise take a decade. For a patient with certain cancers, tumour profiling can identify whether a targeted therapy will work before expensive and gruelling treatment begins. These are real, meaningful applications, not theoretical ones. According to Genomics England, whole genome sequencing has now provided a diagnosis for around 25 per cent of previously undiagnosed rare disease patients who go through the programme. That is not nothing. For those families, it is everything.

    Where the access gaps are widest

    The problem starts with referral. A whole genome sequence only helps if a clinician thinks to order one, knows how to interpret the result, and has access to a genetics specialist who can act on it. Across much of England, particularly in rural areas and in the Midlands and North, that chain is broken at multiple points.

    The NHS has around 3,500 registered clinical geneticists and genetic counsellors in total, according to NHS workforce figures. For a population of 56 million in England alone, that number is inadequate. Most GPs have had minimal genomics training. A 2023 Health Education England review found that fewer than a third of NHS trusts felt their non-specialist clinicians had sufficient understanding to order or act on genomic tests appropriately. That figure has not materially improved since. What this means in practice is that access to NHS genomic medicine in the UK often depends on whether you happen to be treated by a clinician who knows enough to refer you, or who works somewhere with a strong genetics team nearby.

    Geography compounds the problem. The seven Genomic Laboratory Hubs are not evenly spread. Patients in London or Manchester are significantly better served by specialist genetics outpatient services than patients in Cornwall, Lincolnshire or large parts of Wales, where the NHS in Wales has its own separate genomics programme that lacks equivalent infrastructure investment. Health inequality, which runs through almost every part of the NHS, runs through genomics too.

    Ethnicity matters here as well. Genomic reference databases have historically been built predominantly from people of European ancestry. This is a global problem, not unique to the UK, but it means that variant interpretation is genuinely less accurate for patients from South Asian, Black African or other non-European backgrounds. A genetic variant that looks unusual against a European reference population may be entirely normal in a Bangladeshi or Nigerian context, and vice versa. The NHS has made some effort to diversify its datasets, but the 100,000 Genomes Project cohort was roughly 78 per cent white British when analysed. Clinical decisions made from skewed data carry real risk for the patients those datasets underrepresent.

    The data infrastructure problem nobody talks about

    Whole genome sequencing generates enormous quantities of data. A single genome is around 200 gigabytes of raw reads. The NHS Genomic Medicine Service is sequencing tens of thousands of patients per year and that number is rising. Storing, linking, and meaningfully interrogating that data requires infrastructure that the NHS has not historically been designed to support.

    NHS trusts still run a mixture of legacy electronic record systems. Getting genomic data to sit alongside clinical notes, pharmacy records and imaging in a way that a clinician can actually use during a consultation is technically and organisationally difficult. Interoperability between NHS systems is a longstanding problem, and genomics is merely the latest discipline to discover this the hard way. There are also legitimate data governance questions. The public’s trust in NHS data-sharing has been dented by past schemes, and the ICO’s oversight of health data remains a live policy issue, as I’ve written about elsewhere on this blog when covering how health app data privacy works under UK law. Patients are right to ask how their genomic data is stored, who can access it, and whether secondary research use requires their explicit consent.

    The clinician training gap

    Even where the infrastructure exists, many clinicians lack confidence with genomic results. Interpreting a variant of uncertain significance, explaining penetrance to a patient, or deciding whether a finding warrants cascade testing across a family are tasks that require specific training most doctors have not received. Medical schools are only beginning to embed genomics into undergraduate curricula in any meaningful way.

    This matters because NHS genomic medicine cannot scale if it relies entirely on a small group of specialist clinical geneticists. The model that will actually work at population level is one where oncologists, cardiologists, neurologists and paediatricians all have enough genomic literacy to order, interpret and act on tests within their specialty. Building that workforce takes years. The government’s Genome UK strategy, published in 2020, acknowledged this gap and committed to addressing it. The pace of change in medical education, though, has been slow.

    I find it useful to compare this with the self-diagnosis trap that many patients fall into while waiting for specialist input, which I’ve discussed in the context of NHS waiting lists and DIY health decisions. Genomics creates a version of the same pressure. Patients who can afford direct-to-consumer genetic tests from companies like Dante Labs or Genomics PLC are already getting partial information without clinical interpretation. That is not always safe, and it does not replace a conversation with a genetic counsellor.

    What patients can actually expect right now

    If you or your child has a rare undiagnosed condition, asking your GP for a referral to a clinical genetics service is the right first step. The GMS genuinely does deliver for this group, even if waiting times vary by region. For cancer, whether tumour profiling applies to your specific diagnosis depends heavily on cancer type and the capabilities of your treating trust. Haematological cancers and some solid tumours have well-established genomic pathways. Others do not yet.

    For anyone hoping that mainstream preventive genomic medicine, knowing your polygenic risk scores for heart disease, diabetes or dementia before symptoms appear, is an NHS offering today, the honest answer is that it is not. Some pilot studies are running, including work through the NIHR and NHS England’s FH (familial hypercholesterolaemia) programme, but routine preventive genomics on the NHS remains years away for most people. The science is developing faster than the health system’s capacity to deploy it equitably.

    NHS genomic medicine in the UK is genuinely world-leading in places. The ambition behind the GMS is sound. But ambition and delivery are different things, and the patients who most need genomic medicine, those with rare diseases, with harder-to-treat cancers, with family histories that warrant investigation, are often the same patients who face the longest waits, the least-informed clinicians, and the most uneven postcode lottery. Closing that gap requires honest assessment of where the system is actually falling short, not just more press releases about sequencing milestones.

    Frequently Asked Questions

    How do I get a genomic test on the NHS?

    You need a referral from a specialist, typically through a clinical genetics service, an oncologist, or in some cases a paediatrician. GPs can refer you to clinical genetics if there is a relevant family history or suspected rare condition. Not all genomic tests are available through every NHS trust, so access depends partly on where you live and what condition is being investigated.

    What conditions does the NHS Genomic Medicine Service cover?

    The GMS focuses primarily on rare and inherited diseases and cancer genomics, including whole genome sequencing for patients with undiagnosed rare conditions and tumour profiling for certain cancers. It does not currently offer routine preventive or lifestyle genomic testing. The programme is expanding, but coverage varies by region and clinical indication.

    Is NHS genomic data kept private?

    Genomic data collected through NHS programmes is held under NHS data governance rules and subject to UK GDPR, overseen by the ICO. Genomics England operates under a specific data access framework where researchers must apply for access and agree to strict conditions. Patients can request information about how their data is used, and in most cases can opt out of secondary research use.

  • Seed Oils, Saturated Fat and the Online Culture War: What UK Nutrition Science Actually Says

    Seed Oils, Saturated Fat and the Online Culture War: What UK Nutrition Science Actually Says

    If you spend any time on health-focused corners of the internet, you will have encountered the argument: seed oils are poison, they cause inflammation, they are behind every modern chronic disease, and you should throw out your rapeseed oil and replace it with beef tallow immediately. On the other side, you will find people calling that view dangerous nonsense peddled by grifters. Both camps shout loudly. Neither is particularly useful if you are just trying to eat well.

    I want to be straightforward with you here. The seed oils debate is a real scientific question buried under an enormous pile of online culture war. The evidence is not settled in either extreme direction, and UK dietary guidance has not dramatically shifted despite what you may have read. So let us look at what systematic reviews and NHS guidance actually say, and what that means for the oils sitting in your kitchen cupboard.

    Various cooking oils on a kitchen counter, relevant to seed oils health evidence UK
    Photo by Golboo Maghooli on Pexels

    What do we actually mean by seed oils?

    The phrase “seed oils” tends to get used loosely online to mean refined, polyunsaturated vegetable oils, most commonly sunflower, rapeseed, corn, soybean, and similar products. Olive oil, despite technically being pressed from a fruit and sharing some processing characteristics with the others, is usually spared the criticism, presumably because Mediterranean diet research flatters it.

    These oils are high in polyunsaturated fatty acids (PUFAs), particularly omega-6 linoleic acid. The concern raised by critics is that linoleic acid metabolises into arachidonic acid, which can produce pro-inflammatory signalling molecules. That part is biochemically accurate. The leap from there to “seed oils are destroying your health” is where the evidence gets considerably thinner.

    What systematic reviews actually find

    The most robust body of evidence on dietary fat and cardiovascular disease comes from systematic reviews and meta-analyses of randomised controlled trials, not from mechanistic arguments about what a fatty acid does in a test tube.

    A 2020 Cochrane review on reducing saturated fat intake found that replacing saturated fat with polyunsaturated fat, including omega-6-rich seed oils, reduced cardiovascular events by around 17%. The effect on all-cause mortality was less clear, but the cardiovascular signal was consistent across trials. That review looked at over 79,000 participants across 15 trials. It is not a trivial dataset.

    The American Heart Association’s advisory on dietary fats, which draws on much of the same trial literature, reached similar conclusions, though I am more interested in what UK bodies say for obvious reasons. NHS guidance on dietary fats recommends limiting saturated fat and suggests replacing it with unsaturated fats, including oils like rapeseed and sunflower, precisely because the cardiovascular trial evidence supports that swap.

    The SACN (Scientific Advisory Committee on Nutrition), which advises UK government dietary policy, reviewed fat intake in 2019. Its conclusions were consistent with decades of prior guidance: reduce saturated fat, particularly from processed meat and full-fat dairy, and replace with unsaturated alternatives. Seed oils, in that framework, are not the enemy. They are the recommended substitute.

    The oxidation argument and why it needs context

    One of the more credible criticisms of refined seed oils is their instability when heated. Polyunsaturated fats oxidise more readily than saturated or monounsaturated fats at high temperatures, producing compounds including aldehydes that are potentially harmful. A 2015 study from De Montfort University in Leicester, led by Professor Martin Grootveld, found that sunflower oil and corn oil heated to frying temperatures produced significantly more aldehydes than alternatives like olive oil or butter.

    That finding gets amplified in seed oil sceptic circles to mean you should never cook with seed oils. The more measured interpretation is that high-heat cooking with refined polyunsaturated oils is probably not ideal, and alternatives like rapeseed oil (which is lower in polyunsaturates than sunflower), olive oil, or even small amounts of butter are reasonable choices for frying. This is a different claim from “sunflower oil in a salad dressing is damaging your cardiovascular system.”

    Context matters. The UK population is not primarily consuming seed oils through shallow-frying at home. A significant share of dietary intake comes from ultra-processed foods, restaurant meals, and fast food, where the picture is already complicated by salt, refined carbohydrates, and total calorie load. Blaming seed oils in isolation from that broader dietary pattern is intellectually incomplete.

    Where olive oil sits in all of this

    Olive oil is almost universally praised on both sides of the debate, which is itself a bit revealing. It is high in oleic acid, a monounsaturated fat, and extra virgin olive oil contains polyphenols with genuine anti-inflammatory properties backed by multiple trials. The Mediterranean diet, which uses olive oil as its primary cooking fat, has the strongest trial evidence of any dietary pattern for cardiovascular outcomes, including the PREDIMED trial of over 7,000 participants.

    The honest answer is that olive oil is probably the best daily cooking oil for most UK adults if they can afford it and are not cooking at extremely high temperatures repeatedly. Rapeseed oil is a reasonable and cheaper alternative; it has a better fatty acid profile than sunflower oil and is grown domestically. Sunflower oil is fine in moderation for low-heat cooking. None of these is a health catastrophe at normal dietary doses.

    The seed oils health evidence UK debate is genuinely interesting if you approach it without the tribal framing. There are legitimate open questions: the optimal ratio of omega-6 to omega-3 in the diet, the effects of industrial processing on oil quality, the long-term effects of diets very high in linoleic acid. These deserve serious research attention. What they do not justify is the sweeping claim that swapping your rapeseed oil for lard or tallow is a clear cardiovascular upgrade, because the trial evidence does not support that.

    What the noise drowns out

    Debates like this one have a habit of distracting people from changes that would make a measurable difference. The UK population broadly eats too little fibre, too few vegetables, too much processed food, and not enough oily fish. Those patterns carry a well-evidenced cardiovascular and metabolic cost that dwarfs any realistic effect of using sunflower oil instead of olive oil.

    I have written previously on this blog about how inflammation claims around seed oils tend to outpace the evidence, and separately about the risks of using online sources to self-diagnose dietary problems without clinical input. Both feel relevant here. The seed oil conversation lives almost entirely in online spaces where nuance does not travel well.

    If you have a genuine concern about your cardiovascular risk, the productive conversation is with a GP or a registered dietitian, not a social media thread. If your diet broadly follows NHS guidance, includes plenty of whole foods, and uses a variety of fats rather than any single oil in huge quantities, the evidence suggests you are not doing yourself serious harm through your oil choice. That is a dull conclusion, but it is the honest one.

    Frequently Asked Questions

    Are seed oils actually bad for you according to UK health guidance?

    NHS and SACN guidance does not classify seed oils like rapeseed or sunflower oil as harmful. Current UK dietary advice recommends replacing saturated fat with unsaturated fats, which includes these oils. The evidence from systematic reviews supports that swap for cardiovascular health.

    Is cooking with sunflower oil dangerous?

    Sunflower oil produces more oxidation byproducts than olive oil or butter at high frying temperatures, as shown in UK research from De Montfort University. For repeated high-heat cooking, olive oil or rapeseed oil are better choices. Used occasionally at moderate temperatures, sunflower oil is not considered a meaningful health risk.

    Is olive oil healthier than rapeseed oil for UK cooking?

    Extra virgin olive oil has the strongest evidence base, particularly for cardiovascular outcomes, partly due to its polyphenol content. Rapeseed oil is a close and cheaper alternative with a good fatty acid profile and is produced in the UK. Both are sensible choices for everyday cooking.

    Do seed oils cause inflammation?

    Linoleic acid in seed oils can convert to pro-inflammatory compounds via arachidonic acid, but clinical trials have not consistently shown that normal dietary intakes of seed oils raise inflammatory markers in humans. The mechanistic concern is real but has not translated clearly into observable harm in trial populations.

  • Britain’s Sleep Debt Is Getting Worse, and Sleep Hygiene Advice Is Not Fixing It

    Britain’s Sleep Debt Is Getting Worse, and Sleep Hygiene Advice Is Not Fixing It

    Sleep deprivation in UK adults is not a new story, but the data keeps getting worse. The Sleep Council’s Great British Bedtime Report has tracked a steady deterioration in sleep quality across the country for years, and occupational health researchers are increasingly blunt about why: the standard public health messaging around wind-down routines, limiting caffeine after 2pm, and putting your phone face-down at 9pm is not touching the populations most affected. It was never going to.

    I am not dismissing sleep hygiene entirely. For someone whose main obstacle to sleep is an overactive mind or an ingrained habit of scrolling, it has real value. But when the underlying cause is a 4am warehouse shift, a flat above a main road, or the kind of low-grade financial anxiety that does not switch off at bedtime, advice about lavender pillow spray is almost insulting. The problem is structural. The fixes need to match.

    Person lying awake at night illustrating sleep deprivation in UK adults
    Photo by SHVETS production on Pexels

    What the survey data actually shows

    The Office for National Statistics estimated that poor sleep costs the UK economy around £40 billion a year in lost productivity, placing Britain among the worst-performing developed nations for sleep duration. Around a third of UK adults report regularly getting fewer than six hours a night, well below the seven-to-nine hour range most sleep researchers consider the minimum for healthy adult function. The NHS itself acknowledges that one in three people in the UK suffers from poor sleep.

    What those headline figures obscure is the distribution. Sleep deprivation in UK adults is not evenly spread. It clusters around specific populations: shift workers, those in insecure or low-paid employment, people in overcrowded housing, and those with long daily commutes. A 2023 analysis published in the journal Occupational and Environmental Medicine found that workers on rotating shifts had sleep durations averaging 90 minutes shorter than those on standard day schedules. That is not a gap you close with a consistent bedtime.

    Shift work is the single biggest overlooked factor

    Roughly 3.5 million people in the UK work shifts, many of them in logistics, healthcare, retail and manufacturing. For these workers, the circadian disruption is chronic and cumulative. The body’s sleep-wake cycle is governed by light exposure and mealtimes; rotating shifts repeatedly contradict both. I have written before about the metabolic consequences of shift work, which extend well beyond tiredness into increased risks of type 2 diabetes and cardiovascular disease. Sleep is the mechanism through which most of that damage is mediated.

    The difficulty is that most sleep hygiene advice presupposes a fixed schedule. “Go to bed at the same time every night” is biologically sensible but completely irrelevant to someone whose shifts rotate weekly. The more useful interventions for this group are tightly targeted: strategic light therapy to reset the circadian clock before a phase shift, melatonin timed to the new sleep window rather than taken out of habit, and employers scheduling shifts in a “forward rotation” pattern (moving from morning to afternoon to night rather than the reverse), which research suggests the body adapts to more easily. Very few UK employers actually implement the last of these.

    Financial stress and sleep: a relationship the NHS rarely addresses

    Separate from shift work, financial anxiety is one of the most consistent predictors of poor sleep quality in population studies. A 2024 survey by the Money and Mental Health Policy Institute found that 86% of people with problem debt reported that their mental health suffered as a result, with sleep disruption among the most commonly cited symptoms. The mechanism is straightforward: cortisol, the stress hormone, suppresses melatonin production. Chronic financial stress means chronically elevated cortisol at night.

    This is not something a screen curfew addresses. What does move the needle, according to a body of cognitive behavioural therapy research, is structured worry postponement: a technique where people set aside a specific 20-minute “worry window” earlier in the evening to write down and problem-solve financial concerns, actively refusing to engage with those thoughts at bedtime. It is a component of CBT for insomnia (CBT-I), which the NHS recommends ahead of sleep medication but which few GPs have the time or training to deliver properly. The NHS’s own Sleepio programme offers a digital version, though access remains patchy across different integrated care boards.

    Housing quality and the noise problem

    Poor housing is another cause of sleep deprivation in UK adults that receives almost no attention in public health campaigns. Around 8.4 million people in England alone live in non-decent homes, according to the English Housing Survey, and thermal discomfort, damp, noise bleed from neighbouring flats, and proximity to traffic are all independent predictors of disturbed sleep. A terraced house or purpose-built flat in a high-density urban area presents sleep challenges that no amount of white noise apps can fully compensate for.

    There is decent evidence for sound-masking through broadband noise (white or pink noise, not music) when environmental noise is intermittent rather than continuous. Blackout curtains make a genuine difference for those near streetlights. But these are coping strategies, not solutions. The solution is housing stock that meets basic acoustic and thermal standards, which in the UK remains an ongoing policy failure rather than an individual lifestyle choice.

    Long commutes and the hidden sleep tax

    The average UK commuter spends around 59 minutes travelling each day, according to the ONS. For those travelling into London or other major cities, that figure is often much higher. Every additional hour of commuting time comes directly out of either sleep duration or wind-down time at the end of the day. Research from the University of the West of England found that commutes over 45 minutes each way were associated with significantly higher rates of stress, poor sleep and reduced physical activity.

    Remote and hybrid working has helped some workers reclaim that time, but the gains have been unequal. Key workers, those in construction, care, retail, and hospitality, have seen no such flexibility. They are also disproportionately likely to be shift workers or living in lower-quality housing. Sleep deprivation in UK adults concentrates in exactly the populations least able to implement the individual-level advice they are given.

    What actually moves the needle

    CBT-I is the most robustly evidenced intervention for chronic insomnia, with effect sizes consistently larger than sleep medication and without the dependency risks. The National Institute for Health and Care Excellence recommends it as the first-line treatment. The problem is access: most people cannot get it through the NHS in a reasonable timeframe, and private providers charge £100 or more per session. Digital CBT-I programmes are a partial answer, and some integrated care boards are expanding access, but uptake remains low.

    For shift workers specifically, the evidence supports timed melatonin (0.5mg to 3mg taken 30 minutes before the intended new sleep time), forward-rotating shift schedules, and access to blackout sleeping environments. Employers have a legal duty of care under the Health and Safety at Work Act 1974 that extends to fatigue management, yet enforcement is inconsistent.

    At a population level, the levers are rent regulation, improved housing standards, flexible working rights, and transport investment. None of these show up in a sleep hygiene leaflet. My honest read of the evidence is that until public health policy treats sleep deprivation as an occupational and housing problem as much as a behavioural one, we will keep telling people to put their phones down while the actual causes go unaddressed. That is not hopeless, but it does require being honest about where the problem actually sits. The science on conditions like ME/CFS shows clearly what happens when chronic sleep disruption and fatigue are left untreated for years, and the NHS waiting list reality means most people experiencing serious sleep problems are not getting timely support anyway. The gap between need and provision is real, and pretending that individual habit change fills it does nobody any favours.

  • Hypermobility, Chronic Pain and the Decade-Long Wait for Answers: What UK Patients Need to Know

    Hypermobility, Chronic Pain and the Decade-Long Wait for Answers: What UK Patients Need to Know

    If you have spent years being told your joints are ‘just flexible’, that your fatigue is anxiety, or that your pain is disproportionate to what the scans show, there is a reasonable chance hypermobility has never been seriously considered. That is not a fringe experience. For many people with hypermobility spectrum disorder (HSD) or hypermobile Ehlers-Danlos syndrome (hEDS), the path to a meaningful diagnosis runs through a decade of appointments, misdiagnoses and, frequently, being made to feel like the problem is psychological. The hypermobility chronic pain NHS UK picture is improving, slowly, but patients still need to understand what they are dealing with and what they can reasonably expect.

    Woman discussing hypermobility chronic pain with NHS GP during a consultation
    Photo by RDNE Stock project on Pexels

    What hypermobility spectrum disorder actually is

    Hypermobility refers to joints that move beyond the normal range. In children, some degree of flexibility is common and usually harmless. The clinical picture changes significantly when hypermobility comes with chronic pain, fatigue, frequent joint injuries, proprioception problems, and a range of systemic symptoms that do not fit neatly into any single specialty.

    The 2017 international classification separated hEDS from HSD to reflect that these are related but distinct conditions. hEDS is diagnosed using specific clinical criteria around joint hypermobility, skin features and family history. HSD covers patients who have symptomatic hypermobility without meeting the full hEDS criteria. Crucially, both conditions cause real, significant disability. The distinction matters for research purposes but should not imply that HSD is a lesser diagnosis deserving less support.

    Connective tissue is present throughout the body, which is why the symptom list is so wide. Beyond joint pain and instability, many patients deal with gastrointestinal problems, bladder dysfunction, chronic fatigue, and dysautonomia. That last one, particularly postural tachycardia syndrome (PoTS), is underrecognised and often the symptom that sends patients spiralling through cardiology, neurology and psychiatry before anyone joins the dots.

    Why dysautonomia keeps getting missed

    Dysautonomia is a dysfunction of the autonomic nervous system, the part that regulates heart rate, blood pressure, digestion and temperature control. In hypermobile patients, PoTS is the most common form. Standing up causes heart rate to spike by 30 beats per minute or more within ten minutes, producing dizziness, brain fog, nausea and sometimes fainting. The NHS describes PoTS as often taking years to diagnose partly because symptoms mimic anxiety, and partly because lying-down examinations will look completely normal.

    I have spoken to patients who were discharged from cardiology with ‘no structural abnormality’ after a routine ECG, then spent another two years cycling back through their GP before anyone performed a simple active stand test. That test takes minutes. The delay does not reflect a lack of good clinicians; it reflects a system organised around organ-specific specialties that struggles with conditions that are inherently systemic.

    How long does diagnosis actually take in the UK?

    The Ehlers-Danlos Support UK charity has surveyed its members repeatedly and the results are consistent: average time from first seeking help to diagnosis with hEDS or HSD runs to around ten years. That figure has been cited in parliamentary discussions and has not shifted dramatically even as awareness has grown. Part of the delay is structural. There is no single NHS specialty that ‘owns’ hypermobility. Rheumatology, physiotherapy, genetics and pain medicine all have a claim, and which door a patient gets through first is largely down to chance and geography.

    There is also a troubling pattern around gender. The majority of hEDS and HSD patients are women, and the symptoms, particularly fatigue and widespread pain, are historically more likely to be attributed to anxiety or depression in female patients. This is not unique to hypermobility; it is a documented pattern across several chronic conditions. But it compounds the diagnostic delay significantly.

    The fatigue element is worth addressing directly. Many hypermobility patients meet criteria for what was previously called chronic fatigue syndrome. The body is working harder simply to stabilise joints, the autonomic dysfunction disrupts sleep, and pain is itself exhausting. If you are navigating that combination, the situation facing ME/CFS patients in the NHS in 2026 is closely relevant reading, because the service gaps overlap considerably.

    What NICE guidance and NHS specialist pathways actually offer

    NICE does not currently have a dedicated guideline specifically for hEDS or HSD. Management draws on guidance for related conditions: chronic pain (NG193, published 2021), PoTS, and physiotherapy for joint hypermobility. NG193 represents a genuine shift in how the NHS is supposed to approach chronic pain, moving away from purely biomedical models towards personalised care that includes psychological support alongside physical treatment. In practice, implementation is patchy. Pain clinics vary enormously in quality and waiting times.

    For specialist input, NHS England has commissioned a small number of hypermobility clinics, mostly concentrated in London and a few other urban centres. The Hypermobility Unit at the Hospital of St John and St Elizabeth (now operating privately) and the NHS clinic at University College London Hospital are among the most referenced. Outside these centres, most patients are managed in general rheumatology or through physiotherapy alone, which is insufficient for the complexity most of them present with.

    Physiotherapy is the cornerstone of physical management and the evidence supports it, but the emphasis has shifted. Passive stretching is actively counterproductive in hypermobility. Proprioception training, joint stabilisation and carefully progressed strength work are what the evidence points to. The parallel here is worth noting: the case for strength-based exercise in managing chronic musculoskeletal conditions is consistent across the research, much as it is when looking at strength training’s benefits for adults managing chronic conditions later in life.

    Managing chronic pain when the system keeps you waiting

    A realistic read of the current NHS landscape is that most hypermobile patients will not quickly access a specialist clinic. They will manage symptoms partly through physiotherapy, partly through their GP, and partly through their own research. That is not ideal, but it is the current reality.

    A few things are worth knowing. Referral to a genetics clinic can be useful for formal hEDS classification, though waiting lists are long. PoTS, once suspected, can be tested simply with a GP-arranged lying and standing blood pressure and heart rate check. Many GPs will not have initiated this themselves, but they can arrange it once a patient raises it specifically.

    Pacing strategies, borrowed from ME/CFS management, are genuinely helpful for fatigue. The instinct to push through pain on good days and crash on bad ones is understandable but makes the cycle worse. Activity management based on a sustainable baseline, then gradual increments, is the approach most specialist physiotherapists will take.

    Medication for pain is limited in its usefulness. The 2021 NICE guidance on chronic primary pain explicitly moved away from recommending paracetamol, NSAIDs and opioids as the default response, which is significant given how many hypermobility patients have been handed these as a first-line response for years. Low-dose naltrexone and duloxetine are among the options discussed in specialist contexts, but neither is a quick fix and both should be managed with medical oversight.

    Where patient advocacy makes a practical difference

    Ehlers-Danlos Support UK runs helplines, condition guides and connects patients with healthcare professionals who have specific experience. Their resources are genuinely useful for preparing for appointments and understanding what to ask for. The Hypermobility Syndromes Association (HMSA) similarly provides practical support and has a directory of healthcare professionals with relevant experience.

    Self-advocacy is not a phrase that should be needed in a functional health system. But for patients who have spent years being told nothing is wrong, having a clear vocabulary for what you are experiencing, the specific diagnostic criteria, the associated conditions to raise, the tests that are appropriate, makes appointments more productive. It should not be that way. It currently is.

    Chronically complex conditions handled patchily by a stretched NHS tend to push patients towards self-directed solutions, and not all of those solutions are evidence-based. The supplement market is enthusiastic about hypermobility. Magnesium, vitamin C and collagen products are widely marketed to connective tissue disorder patients. Some have a plausible rationale; most lack robust trial evidence in this specific population. If you are thinking through supplementation, the evidence around magnesium deficiency and supplementation in the UK is a reasonable starting point for calibrating expectations.

    The hypermobility chronic pain NHS UK picture is genuinely difficult right now. Awareness is higher than it was, specialist services exist but are limited, and the diagnostic journey remains far too long for too many people. That does not make it hopeless. Physiotherapy, pacing, accurate diagnosis of associated conditions like PoTS, and engagement with patient charities all make a real difference. The wait for systemic improvement continues, but there is more support available today than there was five years ago.

    Frequently Asked Questions

    How do I get referred for hypermobility assessment on the NHS?

    Start with your GP and ask specifically for a referral to rheumatology or a hypermobility clinic if one is accessible in your area. Bringing a clear symptom timeline and mentioning the Beighton score criteria can help focus the conversation. NHS England has commissioned a small number of specialist hypermobility services, though access depends heavily on where you live.

    What is the difference between hEDS and hypermobility spectrum disorder?

    Both involve symptomatic joint hypermobility, but hEDS requires meeting specific clinical criteria set out in the 2017 international classification, including features like skin involvement and a positive family history. HSD is diagnosed when significant symptoms are present but the full hEDS criteria are not met. Both cause real disability and should be taken seriously by clinicians.

    Can hypermobility cause fatigue as well as joint pain?

    Yes, and this is frequently underestimated. The body uses significantly more muscular effort to stabilise hypermobile joints, autonomic dysfunction disrupts sleep quality, and chronic pain is itself draining. Many hypermobility patients meet diagnostic criteria for chronic fatigue conditions alongside their musculoskeletal symptoms.

    What is PoTS and how is it connected to hypermobility?

    Postural tachycardia syndrome (PoTS) is a form of dysautonomia where standing causes a rapid heart rate increase, producing dizziness, brain fog and sometimes fainting. It is significantly more common in people with hypermobile connective tissue disorders. A basic lying and standing heart rate test is usually the first diagnostic step and can be arranged through your GP.

  • Data Brokers, Health Apps and Your Medical Privacy: What UK Law Says and What It Fails to Prevent

    Data Brokers, Health Apps and Your Medical Privacy: What UK Law Says and What It Fails to Prevent

    Most people assume that because a health app is on their phone, and because they vaguely clicked “I agree” at some point, their data is reasonably safe. It is not. Health app data privacy in the UK sits in a genuinely uncomfortable gap between legislation that sounds robust and enforcement that has, so far, been remarkably light. I’ve spent time digging through ICO decisions, GDPR guidance and academic research on this, and the picture is not reassuring.

    Woman reviewing health app data privacy settings on her smartphone
    Photo by Lisa Fotios on Pexels

    What counts as health data under UK GDPR?

    Under the UK GDPR, health data is classed as “special category” data, meaning it attracts stronger legal protections than ordinary personal data. The definition is broader than most people realise. It covers data relating to the physical or mental health of a natural person, including information that reveals their health status. That language matters because it pulls in inferred data, not just data you consciously entered.

    A period tracker that records your cycle dates is processing health data. A fitness app that logs your resting heart rate over time could reveal a cardiac condition. A sleep app that notices you are waking at 3am every night is generating a dataset from which mental health inferences can reasonably be drawn. The app companies know this. What their privacy policies often obscure is what happens to that data after it leaves your phone.

    How health apps actually monetise your data

    The phrase “we may share your data with trusted third parties” is doing a lot of heavy lifting. In practice, the data supply chain from a consumer health app can involve advertising technology platforms, data analytics firms, research organisations and, yes, data brokers who aggregate and resell profiled datasets. The legal mechanism that makes much of this possible is “legitimate interests” under Article 6 of the UK GDPR, combined with consent that was obtained through a consent management platform buried three taps deep in settings.

    Period and cycle tracking apps have received particular scrutiny. A 2021 investigation by Privacy International found that several popular apps were sharing intimately personal data with Facebook’s advertising SDK at the point of app launch, before users had any chance to interact with a consent screen. Some of those apps are still widely used in the UK. The ICO acknowledged concerns about advertising technology broadly in its 2019 report on real-time bidding, but substantive enforcement against health-specific apps has been sparse.

    Digital lock icon representing health app data privacy UK concerns
    Photo by Ann H on Pexels

    What the ICO has and has not enforced

    The ICO has real powers. Under the UK GDPR and the Data Protection Act 2018, it can issue fines of up to £17.5 million or 4% of global annual turnover, whichever is higher. It has used those powers against companies including British Airways and Marriott, though both fines were substantially reduced on appeal. For health app data privacy in the UK specifically, the enforcement record is thin.

    The ICO published its adtech and real-time bidding work and has issued guidance on special category data, but formal enforcement notices specifically targeting consumer health apps or data brokers handling inferred health data remain rare. The regulator has cited resource constraints and the complexity of cross-border enforcement as factors. That is an honest answer, but it leaves a real gap.

    There was a significant moment in 2023 when the ICO issued a reprimand to Snap over its My AI feature, touching on children’s data risk assessments. That reprimand, rather than a fine, illustrated the regulator’s tendency to use softer tools first. For people whose period tracking data or mental health journal entries have already been shared with third parties, a reprimand issued years later feels inadequate.

    The specific risks from period trackers, mental health apps and symptom diaries

    Period trackers carry risks that go beyond embarrassment. Inferred fertility status, pregnancy history or menstrual irregularities can be of interest to insurance underwriters, employers and, in some jurisdictions, law enforcement. UK law offers some protection here: the Equality Act 2010 prohibits discrimination on grounds of pregnancy and maternity, and using health data to discriminate in insurance pricing is tightly restricted by the FCA. But data shared with a broker in a third country, processed under a different legal framework, is much harder to protect.

    Mental health apps sit in a similarly fraught position, and I’d argue they carry the highest reputational risk for the sector. Someone using a mood diary, anxiety tracker or cognitive behavioural therapy app is generating a longitudinal record of their psychological state. If that record is accessible to a data broker, it can be used to build a profile that follows a person across the web. As I covered in an earlier piece on the UK’s mental health app regulation gap, many of these apps operate without any meaningful clinical oversight, which compounds the data problem: there is no regulatory body with clear authority over both the therapeutic claims and the data practices simultaneously.

    Symptom diary apps, the kind people use to track chronic pain, digestive flares, fatigue levels and medication responses, present a third category of risk. These are often used by people with conditions like IBD, ME/CFS or long-term post-viral illness, populations that are already under-served by the NHS and more likely to turn to digital tools to fill the gap. The data generated is clinically detailed. Whether it is being treated with the care that implies is a question most app privacy policies answer evasively.

    What you can actually do right now

    Audit the permissions your health apps hold. On an iPhone, go to Settings, then Privacy and Security; on Android, go to Settings, then Apps, then Permissions. Revoke location and advertising ID access from any health app that does not have an obvious clinical reason to need it. Check whether the app offers an opt-out from data sharing with third parties, and assume the default is opt-in unless you can confirm otherwise.

    Look at where the company is based. An app with a UK company registration and a data protection officer listed on its website is meaningfully more accountable under UK GDPR than one incorporated in a jurisdiction with no equivalent law. You can check company registrations at Companies House in under two minutes.

    Some people navigating health monitoring, especially around recovery, wellness and longevity goals, are also shifting towards hardware and offline supplementation rather than app-based tracking. Based in Nottinghamshire, HealthPod Mansfield supplies hyperbaric oxygen tanks, red light therapy beds and supplements to people who want to actively support their health and live longer without necessarily feeding their data into a subscription app ecosystem. The core appeal for wellness-conscious users is straightforward: you can pursue recovery and health goals using physical equipment at healthpodonline.co.uk without generating a behavioural dataset that a third party can monetise. That is a real consideration, not a minor one.

    The gap that UK law has not closed

    The fundamental problem is that UK GDPR requires lawful basis and transparency, but it does not require that consent be genuinely informed in any meaningful cognitive sense. A 4,000-word privacy policy that mentions data sharing in paragraph 23 is technically transparent. It is not practically transparent. The ICO’s guidance on consent emphasises that it must be freely given, specific, informed and unambiguous, but auditing whether those conditions are met across thousands of consumer apps is not something the regulator currently has the capacity to do systematically.

    There is also the inferred data problem. UK GDPR protects health data you actively input. The question of whether inferred health data, a score calculated from your sleep patterns and heart rate variability that predicts your likelihood of depression, is equally protected is not yet definitively settled in UK case law. The ICO’s position is that inferred data can be special category data if it reveals health information, but that position has not been tested in a major enforcement case specifically targeting consumer health apps.

    People who use apps to manage their health deserve clarity. The current framework provides a legal structure that looks protective but has meaningful gaps in practice. Pushing for stronger enforcement, and being more selective about which apps get access to the most sensitive data you generate, are the two most practical responses available right now. For anyone interested in how digital health tools interact with your personal data more broadly, the NHS waiting list and the self-diagnosis trap piece covers some of the downstream risks when people turn to unregulated tools to fill care gaps, and it is worth reading alongside this one.

    HealthPod Mansfield, known in Nottinghamshire for supplying red light beds and recovery-focused supplements alongside hyperbaric oxygen equipment, represents one end of the spectrum: people choosing be healthy through tangible, offline means rather than through apps that ask for extensive data permissions. Whether or not that approach appeals to you, the underlying instinct to question what health tools actually do with what they learn about you is one more people should develop.

  • Continuous Glucose Monitors Are Being Marketed to Healthy Britons, Here Is What the Evidence Actually Justifies

    Continuous Glucose Monitors Are Being Marketed to Healthy Britons, Here Is What the Evidence Actually Justifies

    Continuous glucose monitors were, not long ago, a clinical tool for people managing type 1 diabetes or unstable type 2. Now they are being advertised on Instagram, sold through wellness subscription services, and worn by healthy thirtysomethings who want to understand their “metabolic health”. In the UK, companies like Levels, Zoe and Supersapiens have made CGM for non-diabetics a genuine consumer category, with prices typically starting around £99 to £200 per month depending on the service. That is real money for what, in many cases, amounts to real-time blood glucose data that a healthy person may have no clinical need for.

    I want to be clear upfront: this is not an attack on the technology. CGMs are genuinely impressive medical devices, and the data they produce is real. The question is whether the interpretation layers being sold alongside them, and the lifestyle changes being recommended on the basis of individual glucose responses, are justified by the evidence we actually have.

    Woman checking CGM for non-diabetics use on her arm in a home kitchen
    Photo by Nataliya Vaitkevich on Pexels

    What CGMs are approved to do in the UK

    The MHRA regulates CGMs as medical devices under the UK Medical Devices Regulations 2002 (as amended). Devices like the Abbott FreeStyle Libre, which is also available on NHS prescription for eligible patients with diabetes, are approved as aids for glucose monitoring in people with diabetes. They are not approved as metabolic optimisation tools for healthy adults. That distinction matters, because it means the claims made in wellness marketing sit outside the scope of what regulators have actually evaluated.

    The Advertising Standards Authority has already taken action against some health brands for making unsubstantiated claims. If you see a CGM subscription service promising it will help you “unlock fat burning” or “end energy crashes”, those are marketing claims, not clinical findings. Treat them accordingly.

    What does the research actually say about CGM for non-diabetics?

    The honest answer is: not much, and what exists is mixed. A 2023 study published in Nature Medicine (the Stanford-led DIETFITS follow-up work examining glycaemic variability) found that individual glucose responses to food varied considerably even among healthy people. That finding has been heavily used by CGM companies to argue that personalised nutrition guidance, informed by your own glucose data, produces better outcomes. But the leap from “glucose responses vary” to “wearing a CGM will improve your health or performance” is not supported by robust clinical trials in non-diabetic populations.

    A 2024 review in The Lancet Diabetes & Endocrinology noted that while CGMs generate large volumes of data in healthy individuals, there is currently insufficient evidence that acting on that data produces meaningful improvements in weight, cardiovascular risk, or athletic performance compared to established dietary approaches. The reviewers called for randomised controlled trials in non-clinical populations before widespread recommendation. We are still waiting for those trials.

    In healthy adults, blood glucose generally stays within a tight range regardless of what you eat. The dramatic-looking spikes that some CGM apps flag as alarming are often physiologically normal. A glucose rise after a bowl of porridge is not the same thing as the sustained hyperglycaemia seen in diabetes. Yet some CGM coaching services treat any excursion above a certain threshold as a problem to be solved through dietary restriction, which risks encouraging unnecessary anxiety about food.

    Smartphone showing blood glucose data relevant to CGM for non-diabetics tracking
    Photo by Tessy Agbonome on Pexels

    The performance claims deserve particular scrutiny

    Supersapiens, which markets its CGM service specifically to athletes, has attracted a following among cyclists, runners, and endurance competitors. The premise is that knowing your glucose in real time helps you fuel more precisely during training and racing. I find this genuinely interesting as a concept. Sports nutrition is a field where small margins matter, and glucose management during prolonged effort is well established as important.

    But “interesting concept” and “proven performance advantage” are different things. The peer-reviewed evidence base for CGM-guided fuelling in non-diabetic athletes is thin. Most sports nutrition guidance from bodies like the British Dietetic Association still centres on periodised carbohydrate intake based on training load and intensity, not real-time glucose response. Until we have properly controlled studies showing CGM-guided fuelling outperforms standard evidence-based nutrition practice in healthy athletes, the claims should be held lightly.

    Who might genuinely benefit from CGM data outside a diabetes diagnosis?

    This is where it gets more constructive. There are populations where CGM use in non-diabetic contexts has real clinical logic. People with prediabetes, those with a strong family history of type 2 diabetes, women with a history of gestational diabetes, and people with polycystic ovary syndrome (PCOS) all have elevated risk profiles where understanding glucose variability has some clinical rationale. For these groups, the conversation belongs with a GP or endocrinologist, not a wellness app.

    If you are curious about your metabolic health and you fall into one of these categories, that is worth raising with your NHS GP rather than self-directing via a subscription service. Given how the NHS waiting list pressures are already pushing people towards self-diagnosis, the last thing anyone needs is another layer of uninterpreted data creating unnecessary worry or driving inappropriate dietary restriction.

    The supplement and nutrition industry connection

    CGM services rarely exist in isolation. Most are bundled with dietary coaching, meal planning, and frequently supplements. Once a company has your glucose data, they have a compelling hook for selling you products designed to “smooth” your glucose response: berberine, cinnamon extract, chromium, and various fibre supplements appear regularly in CGM-adjacent marketing. Some of these have limited supporting evidence in clinical populations; most are sold well beyond what the evidence justifies.

    I came across a comparison tool from Nusan whilst researching how UK consumers are trying to make sense of health product claims more broadly, and the pattern is consistent: the supplement market tends to rush into spaces where clinical data is incomplete and consumer interest is high. CGM is no different. If you are being told by a CGM service that you need specific supplements based on your glucose patterns, ask for the clinical evidence before spending your money.

    This also connects to what I have written previously about the supplement boom needing more scrutiny in the UK generally. The CGM category is just the newest entry point.

    What about Zoe specifically?

    Zoe is the highest-profile CGM-adjacent wellness company in the UK, co-founded by Professor Tim Spector of King’s College London. Their programme involves a CGM, gut microbiome testing, and personalised dietary recommendations. Zoe has published peer-reviewed research, including a 2024 paper in Nature Medicine suggesting their personalised dietary programme outperformed standard healthy eating guidance for certain metabolic markers. That is genuinely more rigorous than most commercial wellness programmes.

    But even here, the research involves Zoe’s own programme participants and has not yet been independently replicated at scale. The scientific advisory involvement does not mean every claim in their marketing is substantiated. The NHS guidance on CGM remains focused on people with diabetes and does not endorse its use in healthy adults for weight or performance management.

    The psychological risk nobody talks about

    One concern I have not seen discussed enough is the psychological effect of continuous metabolic monitoring on people who do not have a clinical reason for it. Wearing a device that generates a new data point every few minutes, and then receiving alerts about “high” readings, could reasonably increase health anxiety in some people. There is also a risk of what researchers call “orthorexic” thinking: becoming so focused on optimising food choices around a metric that eating becomes a source of stress rather than pleasure or nourishment.

    If you are already prone to metabolic health anxiety or have a history of disordered eating, a CGM subscription service is not where I would start. Talk to your GP first.

    The bottom line

    CGMs are legitimate, well-engineered medical devices. The data they produce is real. For people managing diabetes, they are genuinely life-changing. For healthy adults with no clinical indication, the evidence that wearing one and adjusting behaviour accordingly produces meaningful health outcomes is currently insufficient to justify the cost, the anxiety, or the supplement spending that tends to follow. The commercial ecosystem around CGM for non-diabetics has moved considerably faster than the science. That gap is worth understanding before you subscribe.

    Frequently Asked Questions

    Can I get a CGM on the NHS if I don't have diabetes?

    Generally no. NHS CGM prescriptions are reserved for people with type 1 diabetes and some people with type 2 diabetes who meet specific clinical criteria. If you are interested in CGM for metabolic monitoring without a diabetes diagnosis, you would need to purchase it privately through a commercial service.

    Is it safe to use a CGM if I am not diabetic?

    The devices themselves are safe for most people; they involve a small sensor inserted just under the skin. The main risks for non-diabetic users are psychological, including health anxiety from misinterpreting normal glucose fluctuations, and financial, given the ongoing subscription costs. If you have a history of disordered eating, speak to a GP before using one.

    Do CGMs actually help with weight loss in healthy people?

    Current evidence does not support CGM use as an effective weight loss tool in people without diabetes or prediabetes. A 2024 Lancet review found insufficient evidence that acting on CGM data in healthy adults produces better weight outcomes than established dietary approaches. The personalised nutrition framing is compelling, but the clinical proof is not there yet.

  • The UK’s Mental Health App Boom Has a Regulation Problem Nobody Is Talking About

    The UK’s Mental Health App Boom Has a Regulation Problem Nobody Is Talking About

    There are now thousands of mental health apps available to UK consumers. Calm, Wysa, Headspace, Kooth, Woebot, Silvercloud, the list keeps growing. The App Store and Google Play are flooded with products promising to reduce anxiety, improve sleep, treat depression, or help users manage their mood. Some of them are genuinely useful. Some of them are not. And the uncomfortable truth is that most UK consumers have no reliable way to tell the difference, because the framework governing mental health apps regulation UK-wide has serious gaps in it.

    I’ve spent time looking at what oversight actually exists here, and the picture is more fragmented than most people assume. This is not a case of regulators being asleep at the wheel, it is a structural problem built into the way digital health products are classified.

    Person using a mental health app on their smartphone, illustrating the mental health apps regulation UK debate
    Photo by cottonbro studio on Pexels

    What qualifies as a regulated medical device?

    The MHRA (Medicines and Healthcare products Regulatory Agency) oversees software as a medical device (SaMD) in the UK. Since Brexit, the UK has moved away from CE marking for medical devices towards its own UKCA marking, though the MHRA has repeatedly extended transition periods for software. The current framework uses a risk-based classification system: Class I devices are low risk, Class IIa and IIb are moderate risk, and Class III are the highest risk.

    A mental health app that makes a specific diagnostic or therapeutic claim, for example, one that says it is a clinically validated treatment for generalised anxiety disorder, should, in theory, qualify as a SaMD and require MHRA registration. But the classification hinges entirely on the claim the app makes. An app that describes itself as a “wellness tool” or a “mood journal” sits outside that definition, even if its actual functionality is nearly identical to something making clinical claims. Developers are well aware of this, which is why the language used in app store listings is often conspicuously careful.

    The MHRA published updated guidance on software as a medical device in 2023, and it is genuinely thorough. The problem is enforcement capacity and the sheer pace at which new products arrive. Registering a device is not the same as independently verifying the evidence behind it.

    What NICE does, and does not, cover

    The National Institute for Health and Care Excellence has a programme called the Evidence Standards Framework for Digital Health Technologies (DHT), developed in partnership with NHS England. It sets out what evidence digital health tools should provide at different tiers, from simple patient information tools through to products that claim to replace clinical interventions.

    The framework is sound in principle. Tier 3b products, those claiming to treat or diagnose, are expected to provide evidence from randomised controlled trials or equivalent. But participation in the framework is voluntary for commercial products not commissioned through the NHS. An app sold directly to consumers on the App Store has no obligation to submit to NICE review, publish its trial data, or demonstrate that its claimed outcomes hold up in a general UK population. The NHS App Library, which previously listed vetted apps, was quietly wound down. NICE now points users towards a curated but limited set of guidance pages, and the broader consumer market continues largely unvetted.

    Where the CQC fits in, and where it stops

    The Care Quality Commission regulates health and social care services in England, including some digital services. If a mental health app employs regulated professionals who provide clinical advice, a psychiatrist, a psychologist, a counsellor operating under a professional duty of care, the service may fall within CQC registration requirements. But an app that offers automated chatbot therapy, AI-driven cognitive behavioural therapy exercises, or algorithm-generated mood analysis does not automatically require CQC registration, because the service is not being delivered by a regulated professional in a traditional sense.

    This is the gap where a lot of the most popular mental health apps actually sit. The AI element is significant here. As I’ve written before when covering the MHRA’s evolving approach to AI medical devices, the regulatory question of when an algorithm becomes a medical device is genuinely contested. A chatbot that listens, reflects, and suggests breathing exercises exists in a grey zone that neither the MHRA, the CQC, nor any professional regulator definitively owns.

    The evidence problem in practice

    A 2019 review published in npj Digital Medicine analysed 73 depression and anxiety apps available to UK consumers and found that fewer than 4% had been tested in a randomised controlled trial. The situation has improved since, Wysa, for example, has published peer-reviewed studies, and Silvercloud (now Brightside Health) has a reasonable evidence base built from NHS-commissioned research. But the majority of apps in the mental health and wellbeing category make claims that rest on small, industry-funded pilot studies, or no published evidence at all.

    The user reading a five-star review and a vague reference to being “evidence-based” cannot assess the quality of that evidence. And this matters clinically. For someone with mild-to-moderate anxiety who cannot get a GP referral quickly, a reality explored in detail in what I’ve written about the NHS waiting list and the DIY health trap, an app might feel like a reasonable bridge. If the app is genuinely effective, that bridge holds. If it is not, the user may spend months investing time and hope in something that delays them seeking help through other routes.

    There is also a data angle worth taking seriously. Mental health apps collect sensitive personal data at scale: mood logs, sleep patterns, journal entries, sometimes audio. ICO guidance on special category data under UK GDPR applies, and several apps have faced criticism for opaque privacy policies and data sharing arrangements. The ICO and the MHRA technically have overlapping but distinct jurisdictions here, and there is no single point where all of this gets checked together.

    What would actually help

    The honest answer is not more regulation for its own sake. A blanket requirement for every mindfulness app to run a phase three clinical trial would kill useful low-risk tools and drive developers offshore. The more practical solution is clearer labelling and a functional public registry.

    Some version of a tiered trust mark, one that consumers can actually look up and verify, backed by the MHRA or NHS England, would give the market a credibility signal that is currently absent. NHS Digital, before it was folded into NHS England, attempted something like this with the App Library. The logic was right; the execution and resourcing were not.

    For now, my practical advice to anyone considering a mental health app is this: look for published peer-reviewed trials, check whether the app is listed in current NHS England pathways, and treat any app claiming to “treat” a named condition with the same scepticism you would apply to any other unverified therapeutic claim. Apps that are upfront about being wellness tools rather than clinical interventions are being more honest, not less useful.

    The mental health apps regulation UK landscape is not broken in an obvious, dramatic way. It is just porous in ways that are invisible to most users, and that invisibility is the actual problem.

    Frequently Asked Questions

    Are mental health apps regulated in the UK?

    Some are. Apps that make specific clinical or diagnostic claims may need to register with the MHRA as software as a medical device. However, apps marketed as wellness tools fall outside this requirement, which means a large portion of the market operates without formal regulatory oversight of their claimed benefits.

    What does UKCA marking mean for a health app?

    UKCA marking is the post-Brexit UK conformity assessment mark that replaces CE marking for medical devices sold in Britain. For a mental health app, it would signal the product has been assessed against MHRA standards as a software medical device. In practice, transition periods have been extended repeatedly and the mark is rare on consumer-facing apps.

    Does NICE endorse specific mental health apps?

    NICE has an Evidence Standards Framework for Digital Health Technologies, which sets out what evidence apps should provide. However, commercial apps sold directly to consumers are not required to go through this process. Only apps commissioned by the NHS through formal procurement pathways face meaningful scrutiny against NICE standards.

    What data do mental health apps collect and who regulates that?

    Mental health apps typically collect sensitive personal data including mood logs, journal entries, and behavioural patterns. This falls under special category data rules in UK GDPR, regulated by the ICO. However, the ICO and MHRA operate separately, so there is no single point of oversight that covers both clinical claims and data handling together.

    How can I tell if a mental health app is actually evidence-based?

    Look for published peer-reviewed studies in indexed journals rather than vague references to being ‘clinically validated’. Check whether the app appears in NHS England clinical pathways or has been reviewed under the NICE DHT framework. Treat industry-funded pilot studies with caution, and prefer apps that are transparent about the limits of what they can and cannot do.

  • The NHS Waiting List and the DIY Health Trap: Why More UK Patients Are Self-Diagnosing and What It Costs Them

    The NHS Waiting List and the DIY Health Trap: Why More UK Patients Are Self-Diagnosing and What It Costs Them

    The NHS waiting list hit 7.5 million in England by late 2024, and while the numbers have edged down slightly since, millions of people are still waiting months, sometimes over a year, for a specialist appointment. That gap between symptom and consultation does not stay empty. People fill it. They search, they scroll, they ask Reddit, they use AI symptom checkers, and in many cases they arrive at a conclusion long before any clinician sees them. Self-diagnosis during long NHS waiting times has become one of the more significant, and underreported, consequences of the backlog.

    I find this genuinely concerning, not because patients are foolish for doing it, but because the incentives are completely understandable and the risks are largely invisible until something goes wrong.

    Person searching health symptoms online during long NHS waiting times for self-diagnosis
    Photo by VAZHNIK on Pexels

    Why the waiting list is driving people to self-diagnose

    The psychology here is straightforward. Uncertainty is uncomfortable. When a GP refers you to a specialist but cannot tell you what is wrong, and when that referral letter sits in a queue for eight, twelve, sixteen months, the mind looks for answers elsewhere. According to NHS England’s own guidance on elective waiting times, patients referred urgently for suspected cancer should be seen within two weeks, but non-urgent referrals routinely extend far beyond that.

    A 2023 survey by the Nuffield Trust found that almost half of adults in England reported delaying or avoiding GP contact because they expected a long wait. Many went online first. That figure is likely higher now. The average time from GP referral to first outpatient appointment for non-urgent cases sits well above eighteen weeks in many specialities, and in some areas, including orthopaedics and dermatology, patients are waiting considerably longer.

    The result is a predictable loop. Symptom appears. Person waits for GP appointment. GP refers. Person waits again. Person turns to Google, then to a Reddit thread, then possibly to an AI chatbot. By the time the specialist sees them, some patients have already decided what they have, and that framing shapes how they present their history and how receptive they are to a different diagnosis.

    What self-diagnosis actually gets wrong

    This is where the clinical consequences become serious. Self-diagnosis tends to fail in two directions: over-diagnosis (convincing yourself of something rare or serious) and under-diagnosis (reassuring yourself that a concerning symptom is benign). Both carry real costs.

    Research published in the BMJ Open in 2022 assessed the accuracy of online symptom checkers across a range of common presentations. The correct diagnosis appeared in the top three results only around 51% of the time. For rarer conditions, the accuracy dropped further. AI chatbots have improved since then, and I’ve written elsewhere about what actually happens when UK patients use AI tools to interpret their symptoms, but even the better tools are not substitutes for examination, blood tests, imaging or a clinician who can ask a follow-up question based on your expression rather than your typed words.

    GP consultation illustrating the clinical risks of self-diagnosis after NHS waiting times
    Photo by Thirdman on Pexels

    There is also the nocebo problem. Reading extensively about a condition, particularly on patient forums or health anxiety communities, can amplify symptoms. A 2021 paper in Health Psychology Review identified that health-related online searching is associated with increased anxiety and, in some cases, with patients reporting more severe symptoms after researching them. The term “cyberchondria” is used clinically now, not as a dismissal but as a genuine pattern of escalating worry driven by online health information.

    GPs are increasingly reporting patients who arrive with a firm self-diagnosis that is incorrect but fiercely held. This changes the consultation. The GP has to spend time addressing the incorrect belief before they can assess the actual presentation. That takes time that primary care does not have.

    Reddit, Facebook groups and the problem with crowd-sourced health advice

    Online health communities are not inherently harmful. Forums for conditions like ME/CFS or IBD can offer peer support that the NHS simply cannot provide at scale, and I’ve looked at how IBD patients in particular are being let down by poor social media health information. But there is a meaningful difference between emotional support and diagnostic guidance.

    Reddit threads on medical topics are written by anonymous people of unknown clinical background. The most upvoted answer is not necessarily the most accurate one; it is the most engaging, the most confident, or the one that confirmed what readers already believed. A person describing a cluster of symptoms will often receive several different “diagnoses” in the replies, and they will tend to latch onto whichever one fits the narrative they’ve already built.

    This is not a criticism of the people offering help. It is a structural problem with how unmoderated health communities function. Confidence is rewarded. Nuance is boring. And the person who says “I can’t tell from a text description, see your GP” gets fewer upvotes than the person who says “that sounds exactly like X, here’s what worked for me”.

    The supplement and self-treatment rabbit hole

    Self-diagnosis rarely stops at diagnosis. It leads to self-treatment. The UK supplement market was valued at over £500 million in 2024, and a significant portion of that is driven by people treating conditions they believe they have, based on online research. Some of that is harmless. A lot of it is not, particularly where supplements interact with medications or where the underlying condition actually requires treatment.

    I’ve covered how the magnesium supplement boom in the UK has been partly driven by people self-diagnosing deficiency based on vague symptoms that have multiple possible causes. The supplement might do nothing, or it might delay the person from investigating what is actually wrong. In some cases, self-treatment provides enough symptomatic relief that the underlying problem goes unaddressed until it is harder to treat.

    Content monetisation plays a role here too. Publishers and creators who build health content around popular symptom searches are often funded by the very supplement brands their articles recommend. This is a significant conflict of interest that most readers do not notice. Even well-designed content platforms, whether funded by advertising or through affiliate relationships with brands like Banner Ads, can create incentive structures where the editorial framing is shaped by commercial considerations rather than clinical accuracy.

    What patients can actually do while they wait

    None of this means patients should sit passively and wait. There are things worth doing.

    First, keep a symptom diary. Dates, duration, severity, triggers. This is genuinely useful information for a clinician and it gives the waiting period some productive focus. Second, if symptoms change significantly or new ones appear, contact the GP again rather than adding them to your mental self-diagnosis. Third, use the NHS 111 service for acute concerns rather than A&E or Google. It is under-used and designed exactly for the “I’m not sure if this is urgent” scenario.

    If you are using online resources, the NHS website, NICE guidelines and the information sections of established patient charities are substantially more reliable than general forums. Versus Arthritis, the British Heart Foundation, Diabetes UK: these organisations produce patient information that is clinically reviewed and updated. They are not a replacement for medical assessment, but they are a different class of source from a Reddit thread.

    The waiting list problem is real and the frustration driving people to self-diagnose is legitimate. What I’d push back on is the idea that self-diagnosis is a neutral act. It carries clinical risk, psychological cost, and a tendency to narrow the diagnostic conversation before it has even started. The system is failing people. The response to that failure matters too.

    Frequently Asked Questions

    How long is the average NHS wait for a specialist appointment in 2026?

    For non-urgent referrals, many patients wait well beyond the 18-week standard in England, particularly in specialities like orthopaedics, dermatology and rheumatology. In some areas, waits of 12 to 18 months are not uncommon. NHS England publishes monthly waiting time statistics on its website.

    Is self-diagnosing online actually dangerous?

    It carries real risks in both directions. You can over-diagnose something serious and cause significant anxiety, or under-diagnose something that needs prompt treatment. Research published in BMJ Open found symptom checkers gave the correct diagnosis in their top three results only about 51% of the time, which is not a reliable basis for clinical decisions.

    Are AI symptom checkers better than Google for self-diagnosis?

    Modern AI tools are generally more structured than a Google search and can ask follow-up questions, but they still cannot examine you, order tests or account for the full clinical picture. They can be useful for thinking through whether a symptom needs urgent attention, but should not be used to reach a specific diagnosis or guide self-treatment.

    What should I do if my NHS referral is taking a very long time?

    You can ask your GP to check the status of your referral and whether the waiting time is within the 18-week standard. If your symptoms worsen or change while you are waiting, contact your GP again rather than waiting for the appointment. NHS 111 is also available for concerns that feel more urgent.

The Latest